Genelux Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals

– continued active enrollment of olvi-vec in our pivotal phase 3 onprime/gog-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2h 2025 – – initiation of phase 2 trial in non-small cell lung cancer (recurrent/platinum-ici failure) with systemic administration of olvi-vec expected in 1h 2024 – – ongoing phase 1b/2 trial with systemic administration of olvi-vec in small cell lung cancer expected interim readout in 2h 2024 – – $23.2 million in cash, cash equivalents and short-term investments – westlake village, calif., april 01, 2024 (globe newswire) -- genelux corporation (nasdaq: gnlx), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.

- pivotal phase 3 study of olvi-vec in platinum resistant/refractory ovarian cancer initiated in september 2022 - - phase 2 trial of olvi-vec- demonstrated clinical reversal of platinum resistance and refractoriness and met primary endpoint of objective response rate with durable responses - westlake village, calif., nov. 27, 2023 (globe newswire) -- genelux corporation (nasdaq: gnlx), a late clinical-stage immuno-oncology company, today announced that the united states food and drug administration (fda) has granted fast track designation for the development program of olvi-vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.

- expanded executive team as lourie zak appointed chief financial officer -  - extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - westlake village, calif., nov. 14, 2023 (globe newswire) --  genelux corporation (nasdaq: gnlx), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates.

Westlake village, calif., sept. 14, 2023 (globe newswire) -- genelux corporation (nasdaq: gnlx), a late clinical-stage immuno-oncology company, today announced that on september 11, 2023, the company's board of directors (the “board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the company's 2023 inducement plan, including an option to purchase 150,000 shares of common stock to lourie zak, the company's new chief financial officer, an option to purchase 88,000 shares of common stock to caroline jewett, the company's new head of quality, and an option to purchase 54,000 shares of common stock to ralph smalling, the company's new head of regulatory...

Westlake village, calif., sept. 07, 2023 (globe newswire) -- genelux corporation (nasdaq: gnlx), a late clinical-stage immuno-oncology company, today announced that thomas zindrick, president, chairman and ceo, will present a corporate overview with institutional investors during the h.c. wainwright 25th annual global investment conference held the week of september 11t h, 2023.

Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Genelux Corporation (GNLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11t h, 2023.

Genelux recently announced management changes. The company's lead therapy is oncology treatment Olvi-Vec.

Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary candidate, Olvi-Vec, a cancer treatment that targets and destroys cancer cells. The company recently raised $18 million through the private placement of 900,000 shares, and its cash runway is projected to extend into Q1 2026, allowing it to pursue its objectives and strategies. Genelux's Olvi-Vec has shown promising results in clinical trials, demonstrating its capacity to penetrate and multiply within distant tumor sites.

Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.

Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 trial to treat ovarian cancer.

GNLX IPO-ed recently, but the company has been around for two decades. The company develops an oncolytic virus targeting cancer.

Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.